Diabetes
Conditions
Keywords
Blood glucose monitor, Pattern management, Pattern guide, Education
Brief summary
Evaluation of the clinical benefits of One Touch VerioIQ system.
Detailed description
Evaluation of the clinical benefits of the One Touch VerioIQ system. The system contains pattern alert technology and comes with educational material (Pattern guide) which provides additional support and insights to patients and health care providers to help them make more informed decisions during blood glucose management.
Interventions
BGM with pattern alert technology and with associated pattern guide
Sponsors
Study design
Eligibility
Inclusion criteria
* male or female at least 18 to 80 years old * ADA guidelines for FPG and PPG appropriate * A1C greater or equal to 8.0% and less than or equal to 10.5% * lab A1C greater than or equal to 8.0% in the last 6-12mths * Diagnosed with type 1 or 2 in at least last 1 year * on stable dose of OADs for at least 3mths prior to screening * willingness to test 7 BGM tests per day * willing to remain on same therapy as baseline (MDI) for duration of study
Exclusion criteria
* unlikely to be compliant to study procedures * has or has currently used One Touch VerioIQ * Is on fixed doses of insulin for MDI therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in A1C from baseline to week 24 | 24 weeks | A1C (also known as hemoglobin A1C or glycosylated hemoglobin) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in A1C from baseline to week 12 | 12 weeks | — |
| Change in FPG from baseline to 24 weeks | 24 weeks | FPG (Fasting plasma glucose) |
| Change in proportion of subjects with A1C less than or equal to 7.0% at week 24 | 24 weeks | — |
| Change in 30 day mean glucose comparing first month to last month after 24 weeks | 24 weeks | — |